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To-this-date, the exact molecular, cellular, and integrative physiological mechanisms of 
anesthesia remain largely unknown. Published evidence indicates that anesthetic effects 
are multifocal and occur in a time-dependent and coordinated manner, mediated via 
central, local, and peripheral pathways. Their effects can be modulated by a range of 
variables, and their elicited end-effect on the integrative physiological response is highly 
variable. This review summarizes the major cellular and molecular sites of anesthetic 
action with a focus on the paradigm of isoflurane (ISO)  –  the most commonly used 
anesthetic nowadays – and its use in prolonged in vivo rodent studies using imaging 
modalities, such as magnetic resonance imaging (MRI). It also presents established evi-
dence for normal ranges of global and regional physiological cardiac function under ISO, 
proposes optimal, practical methodologies relevant to the use of anesthetic protocols for 
MRI and outlines the beneficial effects of nitrous oxide supplementation.
Keywords: anesthesia, isoflurane, nitrous oxide, rodents, cardiac function, inotropy, lusitropy, magnetic resonance 
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iNTRODUCTiON
Much has been written on volatile (inhalational) anesthetics and their potential mechanisms of 
action. Interestingly, to-this-date, and despite great advances in the field, the exact molecular, 
 cellular, and integrative physiological mechanisms of anesthesia remain largely unknown. With 
the establishment of rodent models as the preferred models for the study of cardiac disease, trans-
genic modifications, and for an increasing number of functional genomics studies, the effects of 
anesthesia on rodents have become paramount for basic science. While the understanding of the 
mechanisms of anesthetic action may be limited, it is critical for normalization and comparative 
studies (to the very least) that the integrative physiological effects are appreciated and considered 
in the design and execution of in vivo disease studies. Unavoidably, the role of in vivo imaging 
and magnetic resonance imaging (MRI) in biomedical research has been increasing, and it is 
envisaged to become integral for future multicenter, consortia, and other targeted image-based 
phenotyping studies.
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It is the purpose of this review to (a) summarize the major 
sites of anesthetic action for in vivo studies at the organ and cel-
lular levels, with a focus on isoflurane (ISO), the most commonly 
used volatile anesthetic (1), (b) present established evidence for 
the normal ranges of global and regional physiological cardiac 
function under ISO, (c) propose optimal, practical method-
ologies relevant to the use of anesthetic protocols for MRI, and 
(d) outline the beneficial effects of N2O supplementation.
We thus present a brief historical overview and a synopsis of 
the existing knowledge of organ, cellular, and molecular mecha-
nisms of anesthetic action, complemented by experimental 
evidence on global/regional cardiac function from recent work, 
in justification of the need to establish and use optimal protocols 
of study.
HiSTORiCAL OveRview AND CURReNT 
KNOwLeDGe ON MeCHANiSMS OF 
ANeSTHeTiC ACTiON
The evolution of Anesthetics – initial 
and Current Hypotheses of 
Mechanisms of Action
The in vivo importance of anesthetics (beyond their narcotic, 
analgesic, and sedative actions) for the study of cardiac func-
tion is reflected upon their effects on regional cellular/organ 
function, and ultimately, upon the elicited integrative physi-
ological response. Despite the reported use of opioids and other 
naturally occurring analgesics in ancient times (2), the Greek 
term anesthesia was introduced later on. This composite term 
indicates the lack of sensation/consciousness (Greek: ανɛυ-
αίσθηση) and dates back to the era of the ancient Greek surgeon 
Dioscorides (3).
In the modern era, nitrous oxide (N2O) was the first synthe-
sized anesthetic in the 1770s by J. Priestley (2, 4). It was subse-
quently used and dubbed by Sir Davy in 1799 as the “laughing 
gas” (4). It was unsuccessfully used to induce general anesthesia 
(primarily due to its low potency as a stand-alone anesthetic) 
by the American dentist Horace Wells in 1845 (2, 4). While 
multiple other attempts on the use of anesthetics were subse-
quently reported, most noteworthy was the successful induction 
of a reversible, insensible state, by Sir Oliver Wendell Holmes 
in 1846 (3), and W. Morton’s first successful public demonstra-
tion of ether-induced anesthesia (5). Inhalational anesthetics 
were developed and introduced later on. ISO became clinically 
available in 1972, with a demonstrated lower solubility in blood, 
than e.g., ether and halothane, and with fast lung elimination 
rates, therefore leading to more favorable pharmacokinetics for 
anesthetic induction and recovery.
Numerous quests had been documented early on to identify 
a single, common biological mechanism of potential targeted 
action, commonly referred and classified as the “unitary hypoth-
esis/theory” (2, 5). Additionally, independent work by Meyer and 
Overton led to the hypothesis of existence of a strong correlation 
between the potency of an anesthetic agent and its lipid solubility 
(that is, its ability to cause perturbations in the lipid bilayer of 
cellular and subcellular structures), commonly known as the 
“Meyer–Overton” rule (6, 7). These two concepts dominated the 
thinking on the mechanisms of anesthetic action for a consider-
able time. However, numerous discrepancies based on experi-
mental observations have led the scientific community to largely 
abandon both concepts. For example, lipid bilayer perturbations 
have also been documented (2, 5, 8) experimentally in vitro by 
temperature increases of less than 1°C (8). Furthermore, use of 
anesthetic stereoisomers have elicited differential effects when 
used in vitro and in vivo, indicating that the primary site of action 
is most likely not the lipid bilayer (8). Correspondingly, there exist 
halogenated alkane compounds (known as “non-imobilizers”) 
that do not obey the Meyer–Overton rule. As stated by Campagna 
et al. (5), collectively, the reasoning for such discrepancies may 
be attributed to anesthetic size, rigidity, polarity variations, and 
the localization of anesthetics within the bilayer. Remarkably, 
even Linus Pauling’s physicochemical clathrate formation theory 
(9) failed to account for the diverse, multifocal, and spatially 
heterogeneous anesthetic localization and actions. The theory of 
lipid solubility of anesthetics has thus largely been abandoned, 
although the hypothesis for gaseous lipid bilayer permeation, dif-
fusion, and bilayer disruption (lipid bilayer–protein interaction) 
is still under investigation (2, 5).
Scientific focus was thus redirected to the possible interactions 
of lipids and structural proteins, but a comprehensive, integrative 
model hypothesis is still lacking (5, 8).
Anesthetic induction and 
Maintenance – Central, Peripheral 
Pathways, and Targeted Organ Sites
Central to their function is their ability to induce a reversible state 
of unconsciousness. Inhalational anesthetics are believed to be 
fast to equilibrate from the onset of induction most likely due to 
the fast exchange at the lung-alveolar/blood capillary interface 
and the fast diffusional transit to the vascular and interstitial 
spaces (10). They exert their effects centrally, on the central 
(supraspinal centers and the cortex) and the peripheral nervous 
systems (spinal cord and neuronal processes), and on the heart, 
liver, and vasculature, in a temporospatial pattern that is likely 
different during induction and recovery (11) (Figure 1).
While the validity of the cognitive binding/unbinding theo-
ries for the disruption of frontoparietal cortical communication 
(12,  13) or imbalances of the excitatory/inhibitory neuronal 
transmission are still under dispute (14, 15), it is currently 
believed that the foundation of unconsciousness is exemplified by 
the integrative disturbance of neuronal pathways, involving the 
reticular formation in the brain stem and supratentorial signaling 
paths, through the mediation of junctional thalamic and corti-
cal regions (2, 16). It is also unknown on whether descending 
cortical or ascending spinal signals exert differential effects on the 
hypnotic action of anesthetics, and if these are dose dependent 
(5). However, what is well established is the spatial distribution 
of inhalational anesthetic accumulation based on tomographic 
PET studies, indicating significant dose-dependent accumula-
tion of ISO in the brain, heart, and liver regions, in support of 
coronary and cerebral blood flow (CBF) increases, and an altered 
metabolism (17) (Figure 1).
HEART
CNS/PNS
LIVER
SPINAL CORD/PNS
VASCULATURE
FiGURe 1 | Major loci of targeted anesthetic action centrally and peripherally.
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Molecular Mechanisms of Anesthetic 
Action via Cellular and Receptor-Mediated 
Signaling Pathways
The molecular basis of anesthetic action involves membrane 
proteins (2, 5, 18–21, 110). Primarily and foremost, molecular 
mechanisms are synaptic, affecting the cysteine-loop superfam-
ily of neurotransmitter receptors and mediating either increases 
of inhibitory postsynaptic excitability or decreases of presynaptic 
(excitatory) neurotransmitter release. Key molecular targets 
are involved in the establishment of unconsciousness and the 
maintenance of hypnotic action, either directly targeting spinal 
and supraspinal centers or cellular entities in the heart and liver, 
and in the peripheral vasculature. Given the disparity of receptor 
types, density, distribution, sensitization, types of binding sites 
and affinities, low-affinity anesthetic interactions, and differ-
ential effects to induction versus recovery, the exact molecular 
effects of mediated action are still unclear. While possible gene 
expression effects have not been investigated in detail, most 
studies have addressed changes in the total conductance of ion 
channels as determined by changes in their innate conductivity 
and open–close probabilities.
The primary inhibitory channels that are likely affected 
by anesthetics include the chloride channels relevant to the 
gamma-aminobutyric acid (GABA)A and glycine receptors and 
two-pore potassium (K2P) channels, including voltage-gated 
(Kv) and adenosine triphosphate (ATP) potassium (KATP) chan-
nels (2, 5, 8, 22, 23). Figure 2 depicts in a comprehensive and 
integrative manner the receptor types mediated in anesthetic 
inhibitory/excitatory action (spanning cellular sites in the 
brain, heart, liver, and other targeted regions). Evidence also 
exists for the modulation of the chlorine channel conductance 
by volatile anesthetics, possibly via indirect action, and most 
likely dependent on Ca2+ changes (22).
On the other hand, excitatory inhibition targets ligand-gated 
nicotinic, muscarinic, amino-3-hydroxy-5-methyl-4-isoxazol-
propionic acid (AMPA), kainate, N-methyl-d-aspartate (NMDA), 
and serotonin (5-HT2 and 5-HT3) receptors (2, 5, 8). Other targets 
include voltage-gated channels, spanning Ca2+ channels [L, T, or 
N and P/Q types, or ryanodine–inositol triphosphate (RyR–IP3) 
receptors], K+ channels (inward rectifiers), or fast activation/
inactivation channels (including Na+ channels). These seem to 
be affected in a diffuse, non-spatially specific manner (negative 
inotropy and chronotropy). Potassium channels have also been 
shown to be involved in the effective action of a2-agonists (cen-
trally or peripherally).
Intracellular Signaling
A reasonable extrapolation of prior evidence for targeted anes-
thetic sites (see prior section) involves pathways and processes 
downstream of cell surface receptors and ion channels. In spite 
of the difficulty in identifying specific anesthetic binding sites 
(as a result of the low-affinity interactions of inhaled anesthetics 
and the lack of knowledge of atomic structures of ion channels 
or membrane proteins), existing evidence stems from work on 
proteins with known structures (e.g., albumin and lusiferase) 
FiGURe 2 | Schematic representation of targeted cellular loci of anesthetic action. This cartoon representation combines receptor-mediated processes specific to cortical, spinal cord, cardiomyocyte, liver, 
and vasculature sites [AMPA, amino-3-hydroxy-5-methyl-4-isoxazol-propionic acid; Cyto, cytochrome c; GABA, gamma-aminobutyric acid; NMDA, N-methyl-d-aspartate; PL, phospholamban; Q, quinone; RyR, 
ryanodine receptor; SR, sarcoplasmic reticulum; SERCA, sarcoplasmic endoplasmic reticulum calcium pump; TnC, troponin C].
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FiGURe 3 | Four of the five known major signaling pathways are triggered by anesthesia (the schematic has been generated based on a relevant 
schematic in Guyton’s textbook on human physiology). For example, effects may be potentiated (signal A) on GABAA or a2-receptors, while ion–channel 
binding may potentiate second-messenger effects (signal D) [cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; DAG, diacyl 
glycerol; PKA, protein kinase A; PKG, protein kinase G; PKC, protein kinase C; CaM, calmodulin; Ser, serine; Thr, threonine].
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(24, 110) or has identified signaling binding sites in protein 
amino acids within neurons (25), protein kinases (26), or in 
mitochondrial complexes III and V (27) (Figure  2). Figure  3 
summarizes the five known, major signaling pathways (28), 
executed through second messengers, protein phosphorylation, 
or G-protein mediated pathways.
Highlighted in Figure 3 are the four cascades that are likely 
triggered or affected by anesthetics (29, 110, 115) with indica-
tive signals identifying GABA receptors for cyclic adenosine 
monophosphate (cAMP)-mediated phosphorylation, glutamate 
receptors for G-protein mediated signaling, and a G-protein 
coupling of a2-adrenergic receptors/agonists.
Anesthetics induce specific potentiation of the activity of 
protein kinase C (PKC) and non-specific inhibition of protein 
kinase A (PKA) (30). Although the spatial distribution and 
subtypes of a2-receptors in rodents are poorly characterized 
(central versus peripheral, pre- versus postsynaptic), there are at 
least three receptor subtypes. Effectively, the molecular signaling 
mechanism is initiated by a2-agonist binding, phosphorylation 
of G-mediated protein Gp, phosphorylation of adenylate cyclase, 
and downregulation of cAMP, thereby leading to downregulation 
of cAMP-dependent kinase and ion–channel conductance altera-
tion, ultimately causing hyperpolarization (Figure 2). The post-
translational phosphorylation of proteins on serine, threonine, or 
tyrosine groups also seems to be plausible (110).
In summary, the primary molecular mechanism of anesthetic 
action is not only the alteration of the chlorine’s channel conduct-
ance but also the conductance of other channels (Ca2+, K+) through 
spatially dependent action in the brain, heart, and other target 
organs, and the periphery. In addition, there are documented 
receptor-mediated channel (via cAMP or PKC phosphorylation) 
and G-protein mediated signaling cascade effects.
CARDiOvASCULAR eFFeCTS OF 
iSOFLURANe AND iNTeGRATive 
PHYSiOLOGiCAL eFFeCTS
Anesthetics have been shown to cause moderate to severe 
cardio-depression (31–38) with adverse physiological effects 
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manifested through dose-dependent contractile changes on 
the heart, brain, and the vasculature, also affecting hormonal 
release (39–41), perfusion, and metabolism (42–45). This sec-
tion briefly summarizes such effects at the global and regional 
cardiac functional levels and through integrative physiological 
action.
Cerebral, Myocardial Perfusion, 
and Coronary Blood Flow
Isoflurane is a potent cerebral (46, 47), coronary (113), and 
peripheral vasculature vasodilator (43, 44). Furthermore, it also 
likely abolishes (in a dose-dependent manner) sympathetic tone, 
although published results from Ebert and Stowe (49) suggest 
that this effect may be spatially heterogeneous, given evidence 
for preservation of sympathetic vasomotor activity.
Spatially heterogeneous CBFs were documented non-inva-
sively in rodents using arterial spin labeling with MRI (46, 47, 
111). In these studies, preferential vasodilation in thalamic versus 
other cortical regions (47) was evidenced, in association with 
documented mean arterial blood pressure (MAP) reductions.
While CBF is tightly regulated by local (myogenic, endothe-
lial, metabolic) and systemic (autonomic, humoral) factors 
(47), and although its changes may be mediated by an interplay 
of numerous factors (43), nitric oxide (NO) release is likely 
involved in the case of volatile anesthetics (46, 47, 50). In justi-
fication of this mechanism was evidence for increased cerebral 
expression levels of NO synthetases post-ISO administration 
(51). However, of interest may be the dose-dependent MAP 
decreases, the differential NO expression levels in the heart 
and peripheral vasculature, and autoregulatory or feedback 
mechanisms for MAP baroreceptor set-point depression and 
stabilization.
Prior PET studies have documented spatial perfusion changes 
in a dose-dependent, serially temporal, uptake manner of ISO 
in the brain, heart (17), gland tissue, kidney, intestine, and liver 
(52), indicative of coronary, cerebral, and other organ blood flow 
increases and altered metabolic profiles.
In fact, significant increases of myocardial blood flow (MBF) 
have been observed under ISO in numerous invasive (48) and 
MRI studies (53) in swine (54), open-chest dogs (55, 56), and in 
isolated (57, 58), and intact rat hearts (53). The coronary vasodila-
tory effects of ISO have been shown to be vascular smooth muscle 
and endothelium-dependent (59), and mediated by KATP channels 
(60, 61). Although the exact mechanism of action is unknown, 
Crystal et  al. (48) have suggested the possibility of (a) direct 
involvement of halogenated anesthetics (sevoflurane, desflurane) 
with KATP channels, (b) ATP decreases in vascular smooth muscle 
cells causing KATP channel opening, (c) a prostacyclin-triggered 
G-protein mediated pathway and KATP channel opening, or 
(d)  adenosine receptor-G-protein, or (e) PKC phosphorylation 
and channel activity modulation.
Overall, it is argued that the net effect of inspired anesthetics 
on CBF may be relevant to the net effect of their vasodilatory 
action versus time-dependent vascular adaptation and meta-
bolic mechanisms secondary to a reduced cardiac workload/
state (48).
Metabolism
Significant reductions in heart rate and lesser reductions in MAP 
from the conscious state are manifested in rodents as a result of 
the use of inhalational anesthetics. As stated above, the potent 
vasodilatory role of some of these anesthetics (e.g., ISO) lead to 
increased blood flows in several vascular beds (17, 52, 62, 114). 
Although changes in the myocardial oxygen extraction 
(EO2) reflect the compound effect of metabolic and vascular 
changes postanesthesia administration, its decreased value 
post-induction (48) hints to possible alterations of metabolic 
status. Correspondingly, the major determinants of myocardial 
oxygen consumption (MVO2) are myocardial contractility, wall 
tension, and heart rate. MVO2 is thus often correlated to the 
product of HR and MAP and regional contractility (48), and it 
is expected to be decreased, but potentially maintained constant 
over prolonged anesthesia exposure (43, 44). This decrease (in 
association to oxygen extraction), directly reflects contractile 
changes (to be discussed below) or metabolic changes, mani-
fested by reductions in the efficiency of ATP production by the 
mitochondria, or both. As reported earlier by Constantinides 
et  al. (43), numerous prior rodent studies have shown that 
inhalational anesthetics decrease glucose metabolic rates as a 
result of the inhibition of ATP synthesis (63), thereby leading to 
the uncoupling of oxidative phosphorylation (23, 27). Impaired 
glucose tolerance, increased glucose, insulin, and glucagon 
levels have also been reported (as a result of altered hepatic 
metabolism and enzyme activity) (43,  64, 112). Sympathetic 
tone and immediate hormonal release postanesthesia induction 
(65) lead to a rapid hyperglycemic effect, results that have been 
observed independently by Constantinides et  al. in C57BL/6 
mice (43). It is unknown on whether such effects are also medi-
ated via direct anesthetic action on the membrane’s glucose/
insulin transporters (Figure 2).
Global and Regional Cardiac Function
Effects of Isoflurane on Global Cardiac Function
The extreme discrepancy between basal cardiovascular function 
in the conscious and anesthetized states in rodents requires care 
in the design and execution of physiological, transgenetic, and 
pathological cardiac studies, especially in cases of non-invasive 
MRI, where prolonged anesthesia is required. In conjunction 
with anesthesia-induced flow reductions, metabolic downregula-
tion, the extreme bradycardic state, and a possible altered cardiac 
functional modus operandi, the assessment of optimal induction 
and anesthetic administration and maintenance over prolonged 
time periods (e.g., ≥90 min) that match most conventional MRI 
protocols becomes critical. In our prior study (43, 44), we have 
accomplished a highly reproducible and stable mouse main-
tenance protocol (beyond 40 min) under ISO at optimal levels 
of approximately 1.5% [mean HR = 478 ± 11.4 and coefficient 
of variability (CV) =  11 ±  1%; mean MAP =  92 ±  2  mmHg, 
CV = 8 ± 2%], following the end of the surgical procedure for 
sensor placements and the reestablishment of thermal stabiliza-
tion (Figure 4).
While lower concentrations of administered ISO (1%) may be 
physiologically preferred, more erratic and highly variable states 
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have been observed. Certainly, higher % doses must be avoided 
in order to avoid severe cardio-depression.
Overall, the observed bradycardic state may be associated with 
direct anesthetic effects on electrical sinoatrial/atrioventricular 
nodal activity and action potential propagation, or possibly 
reflective of the metabolic downregulation and the reduced sym-
pathetic tone (66, 67). The smaller reductions in MAP (compared 
to the conscious state), which is directly dependent on the product 
of cardiac output (CO = HR × SV) and total peripheral resist-
ance (TPR), indicate a well-controlled, systemic, and integrative 
regulation of the blood pressure, and overall increases in TPR. 
The latter are likely manifested by either ISO-related vasomotor 
effects (given the vasodilation observed in different vascular 
beds) and/or blood flow redistribution (43). Shunting of blood 
from one vascular bed to another is extremely fast in the mouse 
and can occur within a period of seconds.
Regional Cardiac Inotropic and Lusitropic  
Effects of Isoflurane
Regional cardiac contractile status (inotropy, lusitropy) is associ-
ated with HR, cross-bridge cycling, sarcomeric force generation, 
and calcium dynamics. Calcium channel entry, sarcoplasmic 
reticulum (SR) storage, calcium-induce and calcium-release via 
RyR receptors, troponin C (TnC) binding, cross-bridge forma-
tion and cycling, and SR pump (SERCA) sequestration are all 
deterministic of calcium homeostasis (Figure 2).
Isoflurane-induced cardio-depression is manifested by chrono-
tropic and inotropic decreases. Modulation of the autonomic tone 
(sympathetic system) mostly accounts for chronotropic effects. 
Correspondingly, decreases of the inward calcium transient and 
SR accumulation/release lead to inotropic changes. The potential 
role of the Frank–Starling law and the force-frequency reserve 
(68–71) has been shown to be less important in mice due to 
their minimal effects. Prior studies in canine and pigs with ISO 
(31, 36) attribute dose-dependent, anesthetic-induced contractil-
ity decreases to diminished contractile protein sensitivity (TnC) 
to calcium binding, altered myofilament responses, and to the SR 
release and reuptake processes (Figure 2).
However, a recent study by Ding et al. (72) in intact and skinned 
right ventricular trabecular muscles in the rat has provided evi-
dence in support of the ISO-induced cardiac force depression as a 
direct result of the decreased myofilament responsiveness to Ca2+. 
TABLe 1 | Summary of reported ranges of normal, regional, physiological 
cardiac indices from invasive catheterization studies using different 
anesthetics.
Cardiac mechanical 
index
Reported 
catheterization 
resultsa
Reference
Heart rate (HR) (bpm) 470–620 Pacher et al. (75)
581 ± 23 Shioura et al. (76)
455 ± 59 Joho et al. (77)
482 ± 43 Reyes et al. (78)
505 ± 19 Yang et al. (79)
634 ± 14 Georgakopoulos et al. (80)
475.5 ± 17.9 bConstantinides et al. (44)
End systolic pressure 
(ESP) (mmHg)
92–118 Pacher et al. (75)
93 ± 2 Shioura et al. (76)
84 ± 10 Reyes et al. (78)
93.5 ± 4.3 Yang et al. (79)
112.1 ± 4.3 Georgakopoulos et al. (80)
102.8 ± 1.5 Constantinides et al. (44)
End diastolic pressure 
(EDP) (mmHg)
1–6 Pacher et al. (75)
7.2 ± 1.0 Shioura et al. (76)
10.2 ± 3.2 Reyes et al. (78)
5.3 ± 0.8 Georgakopoulos et al. (80)
15.5 ± 0.6 Constantinides et al. (44)
End systolic volume 
(ESV) (μl)
7–21 Pacher et al. (75)
20 ± 2 Shioura et al. (76)
18 ± 7 Reyes et al. (78)
11.8 ± 1.1 Constantinides et al. (44)
Cardiac mechanical 
index
Reported 
catheterization 
resultsa
Reference
End diastolic volume 
(EDV) (μl)
25–53 Pacher et al. (75)
33 ± 10 Reyes et al. (78)
15.4 ± 1.1 Yang et al. (79)
22.3 ± 1.2 Constantinides et al. (44)
Stroke volume (SV) (μl) 17–30 Pacher et al. (75)
18.2 ± 1.7 Shioura et al. (76)
18 ± 7 Reyes et al. (78)
8.3 ± 0.7 Yang et al. (79)
14.3 ± 0.3 Constantinides et al. (44)
Ejection fraction (EF) (%) 55–72 Pacher et al. (75)
47.5 ± 2.9 Shioura et al. (76)
53.4 ± 9.9 Reyes et al. (78)
54.7 ± 3.3 Yang et al. (79)
58 ± 14 Georgakopoulos et al. (80)
59.1 ± 2.0 Constantinides et al. (44)
Cardiac output (CO) 
(ml/min)
8–16 Pacher et al. (75)
10.3 ± 7.2 Shioura et al. (76)
8.9 ± 3.3 Reyes et al. (78)
6.8 ± 0.3 Constantinides et al. (44)
dP/dtmax (mmHg/s) 8200–14,200 Pacher et al. (75)
9861 ± 624 Shioura et al. (76)
8738 ± 1659 Reyes et al. (78)
15,967 ± 809 Yang et al. (79)
11,777 ± 732 Georgakopoulos et al. (80)
7912.1 ± 322.6 Constantinides et al. (44)
dP/dtmax/EDV 
(mmHg/s/μl)
180–470 Pacher et al. (75)
343.6 ± 30.3 Constantinides et al. (44)
dP/dtmin (mmHg/s) 6700–10,500 Pacher et al. (75)
−8633±353 Shioura et al. (76)
−6857±990 Reyes et al. (78)
−17,297±1367 Yang et al. (79)
−10,369±909 Georgakopoulos et al. (80)
−8162.1±355.4 Constantinides et al. (44)
Stroke work (SW) 
(mmHg/μl)
1500–2600 Pacher et al. (75)
1349 ± 78 Shioura et al. (76)
598 ± 68 Yang et al. (79)
993.0 ± 29.2 Constantinides et al. (44)
Preload adjusted 
maximum power 
(PAMP) (mW/ml2)
237.6 ± 29.7 Constantinides et al. (44)
Arterial elastance (Ea) 
(mmHg/μl)
3–7 Pacher et al. (75)
5.3 ± 0.6 Shioura et al. (76)
5.4 ± 2.6 Reyes et al. (78)
9.4 ± 1.2 Yang et al. (79)
7.4 ± 0.2 Constantinides et al. (44)
Weiss relaxation 
constant (τweiss) (ms)
4.4–7.6 Pacher et al. (75)
8.7 ± 0.4 Constantinides et al. (44)
Glantz relaxation 
constant (τglantz) (ms)
7–12 Pacher et al. (75)
8.2 ± 0.7 Shioura et al. (76)
3.7 ± 0.2 Yang et al. (79)
6.2 ± 0.5 Georgakopoulos et al. (80)
11.5 ± 0.6 Constantinides et al. (44)
The recent studies by Constantinides et al. and Pacher et al. target ISO-induced 
mouse studies [from Constantinides et al. (44); reproduced from Annals of Biomedical 
Engineering with permission].
aReported values are either min–max ranges or mean ± SD.
bReported values are mean ± SD based on the use of ISO at 1.5% over prolonged 
periods of anesthesia (40–90 min).(Continued)
TABLe 1 | Continued
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The authors also convincingly argue on the possible regulatory 
site of ISO action, attributed primarily on the tropomyosin–actin 
complexation, as mediated by the exposure of actin–myosin 
binding sites during excitation–contraction or by modifying 
soluble cytoplasmic factors that may modulate the myofilament’s 
behavior. The same study shows that myofilament Ca2+ sensitiza-
tion by the nitroxyl (HNO) donor 1-nitrosocyclohexyl acetate 
(NCA) reverses ISO-induced effects and effectively restores force 
development without any concomitant increases in the intracel-
lular calcium (72). Complementary to this study, Fukuto et  al. 
(73) summarize HNO effects in different species, attributing the 
augmentation of Ca2+ release and reuptake from the SR in both 
murine cardiac and skeletal muscles to ryanodine receptors and 
SR Ca2+ ATPase activation (74). It is also argued that calcium 
reuptake in the SR is stimulated by HNO (74). Thus, taken 
together, it is currently unknown on whether the mechanism for 
nitroxyl’s action in  vivo is via a direct effect on the contractile 
proteins and/or modulated by calcium SR cycling, or whether 
species-dependent effects are present.
Regional, in  vivo myocardial contractile performance 
can be characterized based on numerous quantitative, load-
independent, and dependent hemodynamic indices, obtained 
from pressure–volume catheterization studies. Pacher et al. (75) 
have published catheterization protocols for various anesthetics 
(including ISO) and proper hemodynamic ranges of contractile 
function (Table  1). Although these ranges reflect open and 
closed chest preparations and short-term anesthetic exposure, 
Constantinides et al. (43, 44) have extended the study of global 
9Constantinides and Murphy Physiological Effects of Isoflurane Anaesthesia
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functional indices (Figure 4) (44) under optimal and prolonged 
anesthetic conditions (up to 90 min post-induction) to the study 
of regional functional indices (Table 1). These results are in close 
agreement or within the ranges reported by Pacher et  al. (75) 
and indicate constancy of contractile and relaxation performance 
at the regional fiber level, most appropriate for prolonged MRI 
cardiac imaging studies.
THe BeNeFiCiAL USe OF NiTROUS 
OXiDe AS A BALANCiNG AGeNT
Global Organ, Peripheral Stabilization, 
and Molecular effects
Despite its long-lived existence (since the early days of anes-
thetic work) and extensive clinical applicability, the attention 
on the use N2O in basic science has languished and has been 
disproportionately minimal. Its clinical use has been associated 
with the effect of a “second anesthetic.” In effect, the use of 
N2O has been shown to have analgesic properties in humans 
and other species, so it is possible to reduce the administered 
dose of the primary (volatile) agent and thus minimize its side 
effects. However, this has been disputed in the case of mice 
(81). Prior work has indicated that it may exert both cardiac 
and vascular effects. Price (82) has shown that it enhances 
sympathetic activity, counteracting the abolition of the sym-
pathetic tone due to ISO, results that are in agreement with 
Becker and Rosenberg (83), indicating a mild myocardial 
contractility depression offset by activation of the sympathetic 
system. Its synaptic anesthetic, analgesic, and nociceptive CNS 
effects are still questioned (84). Nevertheless, more prominent 
have been the reports supporting vasoconstrictive action 
(both systemic and local) leading to vascular resistance, MAP 
increases (85–87), and stabilization of MAP through preven-
tion of vascular cyclooxygenase expression (87). While human 
studies report N2O-mediated vasodilation subject to increases 
in plasma homocysteine and decreases of endothelial function 
(88), it appears that its beneficial effects on sympathetic tone 
offset such impairments.
Importantly, and in line with the above, are the aforemen-
tioned beneficial effects of HNO reported by Ding et al. (72) in 
conjunction with reports indicating its rapid dimerization to N2O 
(73). Whether the potential added benefits of HNO in vivo are 
direct, and/or mediated via the synthesis of N2O and its action, 
are still unknown.
Our recent study on C57BL/6 mice (43) has documented pro-
longed, consistent, and significant benefits from its supplemental 
use with ISO administration, both in terms of the MAP and HR 
values, and their beat-to-beat variability (Figure 5). Such findings 
have been documented in early work at the National Institutes 
of Health and reproduced in independent catheterization (44) 
and invasive physiological MLP transgenic studies (89). Given 
the lack of proven analgesic effects, the effective supplementation 
of N2O concentration can be much lower than normal, typical, 
clinical levels of approximately 70%. For optimal ISO target doses 
of approximately 1.5 and 75/25% O2/N2O supplementation, we 
have documented 8% increases in mean HR over prolonged 
periods of study (spanning 90  min post-induction) and 2% 
MAP increases compared to mean basal activity at 1.5% ISO 
mixed in 100% O2 (43). More importantly, consistent benefits 
have been documented on the overall variability of mean HR 
in these time periods, yielding decreases in the CV of 36%. The 
practical benefits of such outcomes justify an anticipated appli-
cability of these study protocols in non-invasive studies using 
diagnostic modalities (including MRI, microCT, microPET, and 
ultrasound).
A direct extension of such findings is also expected to have 
impact on the study of the overall heart rate variability (HRV), 
a long-term predictor/biomarker of arrythmogenicity. HRV 
analyses have been implemented and used in mouse pheno-
typic screening studies of normal and transgenic mice, as well 
as the studies of the effects of pharmacologic intervention 
on the  intrinsic heart rhythm and arrythmogenesis (90–92). 
Standardization and interpretation of HRV results in mice 
has been difficult due to the disparity of physiological demo-
graphics (age), other variables (posture), but primarily due to 
circardian and physiological variability (93). To this effect, the 
quantitative measure of the root-mean-square value of the mean 
squared differences between adjacent normal R–R intervals 
(RMSSD) has been studied at various fractional oxygen (FiO2) 
delivery and N2O supplementation levels (45, 94). Noted was 
the balancing effect of N2O, despite an observed increase in 
HR variability (compared to the equivalent FiO2 study) with 
time post- induction. Nevertheless, elicited HRV results com-
pare well with prior reported values in FVB mice under ISO 
(RMSSD = 7.86 ± 0.86) (90), although the exact mechanisms 
responsible for the noted effects are still unknown.
integrative Physiological effects 
of Anesthetics
In summary, anesthetic effects are multifocal and occur in a time-
dependent/coordinated manner, mediated via central and local 
peripheral pathways. Their effects can be modulated by a range 
of variables (such as strain, age, body temperature, and metabolic 
status), and their end-effect on the integrative physiological 
response is highly variable, and thus potentially speculative. 
Nevertheless, drawing on prior published knowledge, the major, 
integrative physiological effects of anesthetics can be summarized 
in the schematic of Figure 6.
MRi OF CARDiAC FUNCTiON UNDeR 
iSOFLURANe
Rodent Phenotyping of Cardiac Function
Cardiovascular MRI of rodents emerged in the 1990s as a natural 
extension of international efforts conducted to map the human 
and mouse genomes (completed in 2001 and 2003, respectively), 
led by the National Institutes of Health. Early studies (95–101) 
progressed through scalability of equipment and hardware used 
for humans and adaptability of existing cardiac imaging pulse 
sequences (conventional gradient echo, spin-echo, and later on 
steady state at free precession) to the mouse/rat. It was soon 
realized that dedicated, high-precision sensors, equipment, and 
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FiGURe 5 | Functional improvements and temporal stabilization of elicited physiological responses as a result of N2O supplementation in the 
anesthetic iSO mixture in C57BL/6 mice. The onset of displayed values has been chosen to be after the completion of the surgical insertion of the recording 
sensors and the thermal stabilization of the mice [Reproduced and adapted from Constantinides et al. (43). By permission from Oxford University Press on behalf of 
the Institute for Laboratory Animal Research. This material is published under a Standard License. Forward reuse is prohibited. For permission, please contact 
journals.permissions@oup.com].
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high-field systems were required for the non-invasive study of 
cardiac function, perfusion, and viability in rodents.
Retrospectively, collective efforts in the study of in  vivo 
cardiac function targeted global (black and bright-blood CINE) 
(98,  101–104) and regional contractile responses (strain and 
velocity imaging) (104–107) in the adult and early embryonic 
stages, in a scientific attempt to progress high-throughput, 
image-based phenotypic screening of wild-type, transgenic, 
and pathological models of cardiac disease. Studies in rodent 
perfusion and viability effectively developed in parallel with cor-
responding human studies.
Despite these early advancements in the field and the emer-
gence of multiple international consortia for integrative evalua-
tion and screening, progress has steadily declined. The envisaged 
future role of image-based phenotyping will entail development 
of regional, molecular, and intrinsic imaging biomarkers that will 
be sensitive to early contractile dysfunction, and that will also 
allow the investigation of spatiotemporal patterns of phospho-
rylation activity, gene expression, and regional/global contractile 
response. To this extent, a closer scientific engagement of genome 
and imaging scientists is envisaged. However, the pace of imaging 
developments currently lacks compared to genetic technological 
advancements.
Correspondingly, the conduct of imaging studies in dedicated 
MRI systems requires adjustments compared to bench-phys-
iological studies, including computer-controlled electrocar-
diograms and breathing, temperature monitoring systems, and 
MR-compatible (fiber-optic, electronic, or pneumatic devices, 
and sensors) and specially designed (with or without negative 
feedback) thermoregulation systems for efficient bore air-heating. 
Dedicated mouse cradles (custom-made or commercially availa-
ble) have also emerged to fit dedicated micro radiofrequency (RF) 
probes, equipped with dedicated nose cones for delivery of the 
anesthetic agent, and connected to specially designed ventilators.
Inevitably, current and future imaging studies are, and will 
be, conducted under anesthesia. Accumulated experience over 
the last two decades indicates that inhalational anesthetics will 
continue to be the preferred choice for prolonged image-based 
phenotyping. Their effects can be potentially detrimental, 
especially for cases of prolonged administration. The following 
section is a brief overview of practical considerations and pitfalls 
relevant to studies under anesthesia.
FiGURe 6 | Proposed integrative physiological responses of anesthesia effects (FS, Frank-Starling; CNS, central nervous system; PNS, peripheral 
nervous system).
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Practical Considerations and 
Anesthetic Protocols
Maintenance of the mouse (or rat) under optimal physiologi-
cal conditions for 60–120  min of anesthesia administration 
for MR imaging is a challenging task. Extreme care must thus 
be exercised for induction, proper anesthetic dose delivery, 
appropriate acclimation of the animal to its imaging environ-
ment, and careful control and monitoring of its temperature 
and vital signs.
Induction
Typical ISO doses range from 3 to 4% over a period of approxi-
mately 2–3 min (until the loss of the righting reflex). Excessive 
and prolonged administration at this dosage level likely leads to 
an initial oversaturation of receptors with ISO causing excessive 
physiological depression that may be difficult to reverse subse-
quently, for instance, if the animal becomes hypothermic.
Surgical Preparation
If dedicated sensors are planned to be used, and surgery is to be 
conducted, it is highly advisable that this takes place as fast as 
possible. Normothermic conditions must be maintained for the 
remaining part of the study and for recovery.
Anesthetic Maintenance and Recording Sensors
All necessary sensors must be efficiently and properly placed in 
the minimum amount of time with ISO maintenance at 1–1.5%. 
If the anesthetic level is set to a higher level, this may induce a 
cardio-depressed state that is difficult to reverse at later times, 
even by decreasing the ISO dosage to lower levels (43). This may 
be related to the anesthetic binding and receptor sensitization, 
or an initial higher cortical MAP set-point depression that is 
difficult to reverse. If, however, such a low-dosage level leads to 
rodent hypersensitivity, agitation, and a light plane of anesthesia, 
it is recommended that the dose is slightly (but temporarily) 
increased to approximately 1.75%, before it is reduced to the 
expected level of approximately 1.5%.
Given the beneficial effects of N2O, it is highly recommended 
that ISO is supplemented with 25% N2O, mixed with 75% O2. 
Active pumping of administered N2O ensures its release to the 
environment. The highly beneficial physiological effects from 
N2O use outweigh costs and technical complexity in this case.
Additionally, enforcement of principles of refinement requi-
res use of MR-compatible carbon fiber (adhesive) electrodes, 
compared to conventional needle ECG. From a technical stand-
point, non-metallic electrodes eliminate induced currents and 
interference during MR gradient pulsations.
12
Constantinides and Murphy Physiological Effects of Isoflurane Anaesthesia
Frontiers in Cardiovascular Medicine | www.frontiersin.org July 2016 | Volume 3 | Article 23
Anesthesia Administration during the Imaging Study
It is highly recommended that variation of the anesthetic dose 
during the imaging study and after the initial steady state has 
been reached is avoided. It is highly risky to perturb the dose 
level since it often (and easily) leads to cardio-depression. From 
a physiological standpoint, perturbations likely lead to changes 
in the anesthesia-receptor sensitization, temporal changes in the 
anesthetic binding–detachment, perturbations of the steady state, 
and induce transient changes that ultimately lead to increased 
physiological variability and inability to stabilize the animal. It is 
highly preferred that a proper, stable, steady, and deep anesthetic 
level is reached early on, and maintained at proper conditions, 
and without a need to modify anesthetic level during the study.
Thermoregulation
Given the low bore temperatures and use of open-bore MRI 
systems, thermoregulation is challenging. Bench studies indi-
cate that the time constant of temperature loss in the mouse 
is much shorter compared to the time constant for attaining 
proper physiological temperature. Even with efficient negative 
feedback systems, it may take several minutes to reach normal 
temperature levels. In contrast, shunting of blood (hyperemic 
responses) and temperature loss (due to the large body surface 
area) is extremely fast and occurs within seconds with important 
potential implications in beat-to-beat blood volume regulation 
and thermoregulation.
Maintenance of Normal Physiological Status
Although most custom-made and commercial systems are based 
on HR and respiration indices for ascertaining proper physiologi-
cal status, HR values may often prove to be misleading as indica-
tive and sensitive biomarkers of normal physiology, masking 
underlying hypotensive states or cardiac contractile downregula-
tion. As discussed earlier, MAP is a more appropriate biomarker, 
while the combination of both HR and MAP is even more useful 
as a potential indicator of myocardial oxygen extraction.
Catheters provide the means to monitor intraventricular 
pressures or monitor hemodynamics during the cardiac cycle; 
however, there are technical challenges (inherent limitations, 
insertion and placement, surgical complexities, MR field inho-
mogeneity artifacts), and their placement imposes physiological 
risks and prolongation of surgical and anesthetic administration. 
Unfortunately, there are no other commercially available sensors 
at present that could easily monitor MAP during imaging studies.
Molecular and Multinuclear imaging
For most imaging protocols for molecular and multinuclear 
MRI, use of inhalational anesthetics has become practically 
highly desirable. For example, from a scientific standpoint, ISO 
administration for in vivo studies of sodium (23Na), phosphorus 
(31P), or potassium (39K) is appropriate. However, there could be 
potential interference of the ISO resonance(s) with 19F fluorinated 
compounds in recent advancements of molecular imaging with 
exogenously administered fluorinated particles (108, 109). In 
these cases, alternative strategies of minimizing or eliminating 
the interference can be successfully implemented through selec-
tive suppression or excitation strategies, or redesign/resynthesis 
of molecular probes to achieve spectral shifts that are far from the 
deleterious contamination of anesthesia.
CONCLUSiON
This review has overviewed the emergence and historical evolu-
tion of major scientific advancements of anesthetics, including 
the receptor-mediated effects on brain, heart, and vasculature, 
and has discussed possible signaling mechanisms triggered by 
inhalational anesthetics. At the organ level, perfusion, metabo-
lism, and global cardiac functional effects have been considered, 
with a focus on the paradigm of MR-based rodent imaging where 
prolonged protocols of study are used, aiming to the establishment 
of optimal, regional, and global indices of cardiac performance.
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